FARN Stock Overview
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Faron Pharmaceuticals Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.18 |
| 52 Week High | UK£3.70 |
| 52 Week Low | UK£1.15 |
| Beta | -0.13 |
| 1 Month Change | -36.22% |
| 3 Month Change | -59.31% |
| 1 Year Change | -63.01% |
| 3 Year Change | -66.29% |
| 5 Year Change | 100.00% |
| Change since IPO | -57.48% |
Recent News & Updates
Shareholder Returns
| FARN | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -7.5% | -2.3% | -0.7% |
| 1Y | -63.0% | -29.4% | -1.8% |
Return vs Industry: FARN underperformed the UK Biotechs industry which returned -29.6% over the past year.
Return vs Market: FARN underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| FARN volatility | |
|---|---|
| FARN Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: FARN's share price has been volatile over the past 3 months.
Volatility Over Time: FARN's weekly volatility has increased from 10% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Markku Jalkanen | www.faron.com |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow.
Faron Pharmaceuticals Oy Fundamentals Summary
| FARN fundamental statistics | |
|---|---|
| Market cap | UK£84.97m |
| Earnings (TTM) | -UK£26.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs FARN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FARN income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €30.94m |
| Earnings | -€30.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -85.1% |
How did FARN perform over the long term?
See historical performance and comparison